First Parkinson's drug to pick its brain receptors more carefully gets FDA approval

The FDA on September 28, 2026 approved tavapadon (brand name Juvmo, AbbVie) for adults with Parkinson's disease, the first Parkinson's treatment designed to engage only a narrow slice of the brain's dopamine system. AbbVie says it expects the once-daily pill to be available in the United States in October.

The drug targets D1 and D5 receptors, the dopamine receptors concentrated in the brain's movement circuits, and largely leaves D2 and D3 receptors untouched. That distinction is the entire bet behind tavapadon. Older Parkinson's drugs, including widely used dopamine agonists like pramipexole and ropinirole, work through the D2/D3 pathway, which is also tied to the impulse-control problems, sudden sleepiness, and hallucinations that have kept many clinicians from prescribing them at full dose.

"The drug targets the receptors that matter for movement, in a way that should reduce the receptors that have caused the side effects," said Zadikoff. The framing is manufacturer-attributed, not an independent comparative safety finding, and the FDA label still lists unusual compulsive urges, hallucinations, orthostatic hypotension, and dyskinesia as adverse reactions to watch for.

The clinical case rests on three Phase 3 trials, all sponsored by AbbVie. In TEMPO-2, which enrolled adults with early Parkinson's not yet on levodopa, patients on 5 to 15 mg of tavapadon had a mean change of -1.5 on the MDS-UPDRS Part II score, a daily-living function measure covering dressing, walking, feeding, and bathing, at 26 weeks, against 0.0 for placebo, with a sponsor-reported p-value of 0.0007. TEMPO-1 covered the same early-Parkinson's population; TEMPO-3 tested tavapadon as an add-on to levodopa in patients already experiencing motor fluctuations, the on-again-off-again swings that mark mid-stage disease.

Those are placebo-controlled, sponsor-reported functional results, not head-to-head wins against existing dopamine agonists or against levodopa itself. The approval covers tavapadon as monotherapy for early Parkinson's and as an add-on to levodopa for patients with motor fluctuations; it does not displace levodopa, which remains the standard first-line treatment.

The prescribing information carries warnings for hallucinations, orthostatic hypotension, dyskinesia, and the same impulse-control behaviors (compulsive gambling, eating, shopping, or sexual urges) that have dogged D2/D3 agonists. The clinical hope is that the rate and severity of those problems lands lower than older drugs'. Whether it does is a question the Phase 3 program was not designed to answer, and the FDA label does not make that claim.

Three things remain genuinely unestablished. The drug's price, formulary placement, and out-of-pocket cost are not yet public, and AbbVie's October availability is an expectation, not a confirmed dispensing date. Real-world uptake will depend on how movement-disorder neurologists weigh the receptor argument against a label whose side-effect list still includes the warnings their older patients already know. And whether a D1/D5-selective agonist changes the disease's course, rather than just treating its motor symptoms, sits outside anything the trial program measured.

Tavapadon now joins the Parkinson's cabinet as one more option with a cleaner mechanistic story than the D2/D3 agonists that came before it. Whether prescribers reach for it before those older drugs will depend on real-world tolerability, which the trial program was not designed to compare head-to-head.